DonnaKo

Associate

Hong Kong + 852.2526.6895

Connect:

Share

Donna Ko advices on M&A, capital markets (including listings and public offerings), securities regulatory compliance, joint ventures, and other commercial transactions across Hong Kong, mainland China, and the Asia-Pacific region.

Prior to joining Jones Day in 2017, Donna practiced at two leading international law firms.

Experience

  • Marubeni sells global grain business of Gavilon Agriculture InvestmentJones Day advised Marubeni Corporation in the sale of the global grain business of Gavilon Agriculture Investment, Inc. to Viterra Limited, following a reorganization of Gavilon’s structure.
  • China Post Group Limited invests $128 million in Ule Holdings LimitedJones Day advised China Post Group Limited with its $128 million investment in Ule Holdings Limited through Telpo Philatelic Company Limited ("Telpo"), a subsidiary of China Post.
  • GenScript Biotech Corporation completes US$402 million follow-on offering by Legend Biotech CorporationJones Day represented GenScript Biotech Corporation in connection with a US$402 million follow-on offering by its Nasdaq-subsidiary Legend Biotech Corporation (NASDAQ: LEGN).
  • GenScript Bio's non-wholly-owned subsidiary Probio Technology Limited raises $37 million in Series B financingJones Day represented GenScript Biotech Corporation (HK Stock Code: 1548) ("GenScript Biotech") in the $37 million Series B financing of non-wholly-owned subsidiary Probio Technology Limited ("Probio Cayman"), led by Zhenjiang High-tech Venture Capital (HK) Limited.
  • PTTGC acquires allnex from AdventJones Day advised PTT Global Chemical Public Company Limited in the €4 billion acquisition of allnex Holding GmbH from Advent International.
  • GenScript Biotech Corporation completes US$344.6 million follow-on offering by Legend Biotech CorporationJones Day represented GenScript Biotech Corporation in connection with its US$344.6 million follow-on offering by its NASDAQ-subsidiary Legend Biotech Corporation.
  • GenScript Biotech and its subsidiaries Legend Biotech and ProBio Cayman complete US$1.07 billion investment by Hillhouse CapitalJones Day represented GenScript Biotech Corporation (“GenScript Biotech”), its controlling shareholder GenScript Corporation, and its two subsidiaries Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) and Probio Technology Limited (“Probio Cayman”) in connection with a US$1.07 billion investment by Hillhouse Capital.
  • EagleTree Capital acquires IntegreonJones Day advised EagleTree Capital in connection with the acquisition and financing of Integreon, a leading global managed services provider, from NewQuest Capital Partners.
  • Solmax acquires TenCate GeosyntheticsJones Day advised Groupe Solmax Inc. (Solmax), the global leader in the production of high-quality polyethylene geomembranes for industrial and environmental applications, and its shareholders (including institutional investors Caisse de dépot et placement du Québec and Fonds de Solidarité FTQ), in connection with Solmax’s acquisition of TenCate Geosynthetics Holding B.V., a global provider of geosynthetics and industrial fabrics, from Dutch conglomerate Koninklijke Ten Cate (Royal Ten Cate, the Netherlands), and advised on the related senior secured financing to support the acquisition.
  • ETS acquires VericantJones Day advised Educational Testing Service in its acquisition of Vericant, a provider of secure, verified in person interviews and Spoken English Evaluations worldwide.
  • Orocobre raises A$156 million by way of placement and share purchase planJones Day advised Orocobre Limited, a dual ASX and TSX-listed lithium chemicals producer, on a A$156 million capital raising by way of a fully underwritten placement to institutional investors of A$126 million and non-underwritten share purchase plan to shareholders in Australia and New Zealand of up to A$30 million.
  • GenScript Biotech Corporation completes US$423.8 million IPO and spin-off of its subsidiary Legend Biotech Corporation; and US$24 million purchase of Ordinary Shares of Legend BiotechJones Day acted as the U.S. and Hong Kong legal advisors of GenScript Biotech Corporation (“GenScript Biotech”) in relation to its (a) approximately US$423.8 million initial public offering of 18,425,000 American Depositary Shares and spin-off listing of its subsidiary Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) on the Nasdaq Global Select Market and (b) approximately US$24 million purchase of Ordinary Shares of Legend Biotech in a concurrent private placement of Legend Biotech.
  • JinkoSolar sold two solar photovoltaic (PV) plants in Mexico to White River RenewablesJones Day advised JinkoSolar Holding Co., Ltd., one of the world's largest and most innovative solar panel manufacturers, in the sale of two solar photovoltaic (PV) plants in Mexico to White River Renewables.
  • UCB completes €3 billion EMTN ProgrammeJones Day advised UCB S.A. in connection with the set-up of their €3 billion EMTN Programme for issuance of notes.
  • PETRONAS Chemicals acquires Da Vinci Group B.V. for €163 millionJones Day advised PETRONAS Chemicals Group Berhad (PCG) in its acquisition of a 100% stake in Da Vinci Group B.V. from its shareholders including funds managed by Bencis Capital Partners for €163 million.
  • GenScript Biotech Corporation completes placement of sharesJones Day advised GenScript Biotech Corporation (the “GenScript”, together with its subsidiaries, the “GenScript Group”), a company listed on The Stock Exchange of Hong Kong Limited, on its US$255 million top-up placing of shares and Ms. Ye Wang, a director, president, and controlling shareholder of GenScript on her US$51 million placing of shares.
  • Haitong International Financial Products invests $20 million in Burwill Holdings LimitedJones Day represented Haitong International Financial Products (Singapore) Pte Ltd in connection with its subscription of $20 million of 7% Convertible Bonds in Burwill Holdings Limited, a Hong Kong-based investment holding company principally engaged in steel trading.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.